Proton Pump

Related Products

Proton pump is an integral membrane protein that is capable of moving protons across a biological membrane. Mechanisms are based on conformational changes of the protein structure or on theQ cycle. In cell respiration, the proton pump uses energy to transport protons from the matrix of the mitochondrion to the inter-membrane space. It is an active pump, that generates a protonconcentration gradient across the inner mitochondrial membrane, because there are more protons outside the matrix than inside. The difference in pH and electric charge (ignoring differences inbuffer capacity) creates an electrochemical potential difference that works similar to that of a battery or energy storing unit for the cell. The process could also be seen as analogous to cycling uphill or charging a battery for later use, as it produces potential energy. The proton pump does not create energy, but forms a gradient that stores energy for later use.

Proton Pump Related Products (174)
Antibodies (1)

By Effects:	Controls (3) Inhibitors (150) Agonists (3) Antagonists (3) Activators (2)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-P3278A

Caloxin 2A1 TFA	Inhibitor	99.92%
Caloxin 2A1 TFA is an extracellular plasma membrane Ca²⁺-ATPase (PMCA) peptide inhibitor. Caloxin 2A1 TFA does not affect basal Mg²⁺-ATPase or Na⁺-K⁺-ATPase.

HY-17023

Esomeprazole sodium	Inhibitor	99.88%
Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H⁺, K⁺-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H⁺-ATPases. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research.

HY-101664

Ilaprazole	Inhibitor	99.97%
Ilaprazole (IY-81149) is an orally active proton pump inhibitor. Ilaprazole irreversibly inhibits H⁺/K⁺-ATPase in a dose-dependent manner with an IC₅₀ of pump inhibitory activity of 6 μM in rabbit parietal cell preparation. Ilaprazole is used for the research of gastric ulcers. Ilaprazole is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor.

HY-N2532

Diphyllin	Inhibitor	99.90%
Diphyllin is an orally active V-ATPase inhibitor (IC₅₀=17 nM) and HIV-1 inhibitor (IC₅₀=0.38 μM). Diphyllin blocks the acidification of osteoclast lysosomes and bone resorption lacunas (IC₅₀=0.6 nM for acid influx inhibition)， thereby inhibiting bone resorption. Diphyllin can effectively inhibit osteoclast-mediated bone resorption and has no effect on osteoblastic bone formation. Diphyllin can be used in the research of bone metabolism-related diseases and has the potential to inhibit diseases related to excessive bone resorption.

HY-100007

Vonoprazan	Inhibitor	99.40%
Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H⁺,K⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori.

HY-135474

KM91104	Inhibitor	99.67%
KM91104, a cell-permeable V-ATPase inhibitor, specifically targets the a3-b2 subunits of V-ATPase.

HY-109079A

Abeprazan hydrochloride	Inhibitor	99.87%
Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H⁺, K⁺- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases.

HY-17623

Tegoprazan	Inhibitor	99.76%
Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a reversible, orally active and highly selective inhibitor of gastric H⁺/K⁺-ATPase. Tegoprazan inhibits gastric acid secretion and motility against porcine, canine and human H⁺/K⁺-ATPase with IC₅₀ values ranging from 0.29-0.52 μM in vitro. Tegoprazan significantly improves colitis and enhances the intestinal epithelial barrier function in mice. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases.

HY-111974

β-D-Glucopyranosyl abscisate	Agonist
β-D-Glucopyranosyl abscisate (ABA-GE) is a hydrolyzable abscisic acid (ABA) conjugate that accumulates in the vacuole and presumably also in the endoplasmic reticulum. The deconjugation of β-D-Glucopyranosyl abscisate allows the rapid formation of free ABA in response to abiotic stress conditions such as dehydration and salt stress. β-D-Glucopyranosyl abscisate contributes to the maintenance of ABA homeostasis.

HY-B0656

Rabeprazole	Inhibitor	99.14%
Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H⁺/K⁺-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC₅₀ of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux.

HY-P2657

Verucopeptin	Inhibitor
Verucopeptin is a potent HIF-1 (IC50=0.22 μM) inhibitor and decreases the expression of HIF-1 target genes and HIF-1α protein levels. Verucopeptin strongly inhibits v-ATPase activity by directly targeting the v-ATPase ATP6V1G subunit but not ATP1V1B2 or ATP6V1D. Verucopeptin exhibits antitumor activity against multidrug resistance (MDR) cancers and can be used for cancer research.

HY-100414

Soraprazan	Inhibitor	99.78%
Soraprazan (BYK61359) is a selective, reversible K-competitive inhibitor of the H,K-ATPase (K_i=6.4 nM), with an IC₅₀ of 0.19 μM in gastric glands. Soraprazan binds to the H,K-ATPase with a Kd of 28.27 nM. Soraprazan shows immediate inhibition of acid secretion and is more than 2000-fold selective for H,K-ATPase over Na,K- and Ca-ATPases.

HY-P3278

Caloxin 2A1	Inhibitor	99.86%
Caloxin 2A1 is an extracellular plasma membrane Ca²⁺-ATPase (PMCA) peptide inhibitor. Caloxin 2A1 does not affect basal Mg²⁺-ATPase or Na⁺-K⁺-ATPase.

HY-B2145

Ilaprazole sodium	Inhibitor	99.84%
Ilaprazole (IY-81149) sodium is an orally active proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H⁺/K⁺-ATPase in a dose-dependent manner with an IC₅₀ of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium is used for the research of gastric ulcers. Ilaprazole sodium is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor.

HY-17623C

(R)-Tegoprazan	Inhibitor	99.73%
(R)-Tegoprazan ((R)-CJ-12420; example 3), a benzimidazole derivative, is a potent kidney H⁺/K⁺-ATPase inhibitor with an IC₅₀ of 98 nM of canine kidney Na⁺/K⁺-ATPase. (R)-Tegoprazan has the potential for gastrointestinal diseases research.

HY-109079

Abeprazan	Inhibitor	99.86%
Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H⁺, K⁺- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases.

HY-17022

Esomeprazole magnesium trihydrate	Inhibitor	99.62%
Esomeprazole magnesium trihydrate ((S)-Omeprazole magnesium trihydrate) is a potent and orally active H⁺, K⁺-ATPase inhibitor. Esomeprazole magnesium trihydrate has the potential for upper intestinal disorders and gastroesophageal reflux disease research. Esomeprazole magnesium trihydrate acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H⁺-ATPases.

HY-139557

Zastaprazan	Inhibitor	99.96%
Zastaprazan (JP-1366) is a proton pump inhibitor (WO2018008929). Zastaprazan can be used for the research of gastrointestinal inflammatory diseases or gastric acid-related diseases.

HY-N7067

Revaprazan hydrochloride	Inhibitor	99.98%
Revaprazan hydrochloride is reversible proton pump inhibitor. Revaprazan hydrochloride can inhibit gastric acid secretion and protect gastric mucosa. Revaprazan hydrochloride can inhibit IkappaB-alpha degradation as well as Akt inactivation, resulting in attenuation of H. pylori-induced COX-2 expression. Revaprazan hydrochloride can be used for the researches of infection and inflammmation, such as H. pylori-infected gastric inflammation and gastric ulcer.

HY-P10655

Caloxin 1C2	Inhibitor	98.86%
Caloxin 1C2 is a specific PMCA (plasma-membrane Ca²⁺-ATPases) inhibitor. Caloxin 1C2 is selective for PMCA4 over PMCA1, 2 and 3. The K_i values of Caloxin 1C2 are 2.3 μM for PMCA4 and 21 μM for PMCA1. Caloxin 1C2 dose not cause any significant effects on total Ca²⁺ transfer. Caloxin 1C2 affects coronary contractility.

Name
Email *

	Sorry, but the email address you supplied was invalid.

Proton Pump

Proton Pump

Proton Pump Related Products (174)

Antibodies (1)

Proton Pump Related Products (174):